Literature DB >> 24320129

The bioanalytical challenge of determining unbound concentration and protein binding for drugs.

Lars B Nilsson1.   

Abstract

Knowledge regarding unbound concentrations is of vital importance when exploring the PK and PD of a drug. The accurate and reproducible determination of plasma protein binding and unbound concentrations for a compound/drug is a serious challenge for the bioanalytical laboratory. When the drug is in equilibrium with the binding protein(s), this equilibrium will shift when physiological conditions are not met. Furthermore, the true unbound fraction/concentration is unknown, and there are numerous publications in the scientific literature reporting and discussing data that have been produced without sufficient control of the parameters influencing the equilibrium. In this Review, different parameters affecting the equilibrium and analysis are discussed, together with suggestions on how to control these parameters in order to produce as trustworthy results for unbound concentrations/fractions as possible.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24320129     DOI: 10.4155/bio.13.274

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  3 in total

1.  Unbound Fraction of Clozapine Significantly Decreases with Elevated Plasma Concentrations of the Inflammatory Acute-Phase Protein Alpha-1-Acid Glycoprotein.

Authors:  Wai Hong Man; Ingeborg Wilting; Eibert R Heerdink; Gerard W K Hugenholtz; Tim Bognár; Maarten J Ten Berg; Wouter W van Solinge; Toine A C G Egberts; Erik M van Maarseveen
Journal:  Clin Pharmacokinet       Date:  2019-08       Impact factor: 6.447

2.  Saturation monitoring of VX15/2503, a novel semaphorin 4D-specific antibody, in clinical trials.

Authors:  Terrence L Fisher; Jennifer Seils; Christine Reilly; Virginia Litwin; Lisa Green; Janelle Salkowitz-Bokal; Robin Walsh; Sarah Harville; John E Leonard; Ernest Smith; Maurice Zauderer
Journal:  Cytometry B Clin Cytom       Date:  2015-12-24       Impact factor: 3.058

3.  Quantification of unbound concentration of ticagrelor in plasma as a proof of mechanism biomarker of the reversal agent, MEDI2452.

Authors:  Ann-Sofie Sandinge; Annika Janefeldt; Susanne Pehrsson; Sven Nylander
Journal:  PLoS One       Date:  2018-07-26       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.